Concepedia

Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database

Amichai Perlman, Samuel N. Heyman, Ilan Matok, Joshua Stokar, Mordechai Muszkat, Auryan Szalat

Nutrition Metabolism and Cardiovascular Diseases · 2017 · 91 citations · 18 references

DOI

Concepts

References

18

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

, , +17

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text

, , +17

Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

Stephen Evans, Patrick Waller, Sarah Davis · Pharmacoepidemiology and Drug Safety · 2001 · 1.7K citations

, , +16

Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes

Hiddo J.L. Heerspink, Dick de Zeeuw, Li Wie et al. · Diabetes Obesity and Metabolism · 2013 · 831 citations · Full text

, , +17